SLOAN HARRY 4

What Happened

• Harry Sloan, a non-employee director of Ginkgo Bioworks Holdings, Inc. (DNA), received a grant of 25,000 restricted stock units (RSUs) on June 11, 2026. The RSUs are a derivative award (no per-share price reported) that represent a contingent right to receive one share of Class A common stock per RSU upon vesting. This is a compensation award rather than an open-market buy or sale.

Key Details

• Transaction date: 2026-06-11; Form 4 filed: 2026-06-15.
• Transaction type: Award/Grant (code A); amount: 25,000 RSUs; price: N/A (derivative).
• Vesting: RSUs vest on the earlier of June 11, 2027 or the day before the next annual meeting after the grant, contingent on continued service as a non-employee director (per filing footnotes).
• Footnotes: F1 clarifies each RSU equals a contingent right to one share; F2 describes the vesting schedule tied to director service and the Amended and Restated Non-Employee Director Compensation Program effective June 11, 2026.
• Shares owned after transaction: Not specified in the provided filing details.
• Timeliness: Form filed four days after the transaction date (filed 2026-06-15 for a 2026-06-11 grant).

Context

• RSU grants to non-employee directors are commonly part of routine director compensation and do not by themselves indicate buying or selling sentiment by management. Upon vesting, each RSU converts to one share (subject to the plan terms and continued service).